<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12737/article_5955e6b60d5bf2.66416553</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>САХАРНЫЙ ДИАБЕТ 2-ГО ТИПА И ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА</article-title><trans-title-group xml:lang="en"><trans-title>TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бардымова</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Bardymova</surname><given-names>T. P.</given-names></name></name-alternatives><email xlink:type="simple">tpbardymova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Протасов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Protasov</surname><given-names>K. V.</given-names></name></name-alternatives><email xlink:type="simple">k.v.protasov@gmail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыреторова</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsyretorova</surname><given-names>S. S.</given-names></name></name-alternatives><email xlink:type="simple">tsyretorova.seseg@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Донирова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Donirova</surname><given-names>O. S.</given-names></name></name-alternatives><email xlink:type="simple">donirova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Иркутская государственная медицинская академия последипломного образования - филиал ФГБОУ «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГАУЗ «Республиканская клиническая больница им. Н.А. Семашко» Министерства здравоохранения Республики Бурятия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.A. Semashko Republic Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2017</year></pub-date><volume>2</volume><issue>1</issue><fpage>100</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бардымова Т.П., Протасов К.В., Цыреторова С.С., Донирова О.С., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Бардымова Т.П., Протасов К.В., Цыреторова С.С., Донирова О.С.</copyright-holder><copyright-holder xml:lang="en">Bardymova T.P., Protasov K.V., Tsyretorova S.S., Donirova O.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/372">https://www.actabiomedica.ru/jour/article/view/372</self-uri><abstract><p>Сахарный диабет приобретает масштабы эпидемии. Наблюдается рост числа больных ишемической болезнью сердца, страдающих сахарным диабетом 2-го типа. При наличии сахарного диабета усугубляется течение ишемической болезни сердца в виду прогрессирования атеросклероза. В развитии атеросклероза отмечается роль цитокинов, которые являются отражением местного и системного воспаления. Инсулинорезистентность, гиперфибриногенемия, дислипидемия у больных сахарным диабетом усиливают риск неблагоприятных исходов ишемической болезни сердца.</p></abstract><trans-abstract xml:lang="en"><p>In recent years, the growth in the number of diabetic patients has been registered in the most countries. In turn, the diseases of the cardiovascular system are still the leading cause of death in many countries. Against the background of rapid growth in the incidence of diabetes mellitus, the number of patients with combined pathology including coronary heart disease and type 2 diabetes mellitus increases. Oxidation of LDL with the subsequent generation of cytokines and other biologically active molecules is considered one of the major pathogenic mechanisms of atherosclerosis. Hyperglycemia contributes to the processes of lipid peroxidation with activation of atherogenesis with increased risk of vascular lesions. The modern views on commonality of the mechanisms of the development of diabetes and coronary heart disease are studied. Attention is paid to the generation of free radicals, which being highly reactive unstable chemical compounds damage the endothelium. However, activation of free radical processes in the conditions of hyperglycemia stimulate the increased synthesis of pro-inflammatory cytokines, including necrosisfactor-a tumor, interleukins, which are a reflection of local and systemic inflammation. This review presents detailed description of the main pro-inflammatory cytokines (interleukin-1ß, interleukin-6, interleukin-8, TNF-a) and C-reactive protein. The value of insulin resistance and hyperfibrinogenemia in diabetes mellitus combined with coronary heart disease and the factors, which increase the risk for adverse outcomes of coronary heart disease, is presented in the article.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2-го типа</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>дисфункция эндотелия</kwd><kwd>цитокины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>coronary heart disease</kwd><kwd>endothelial dysfunction</kwd><kwd>cytokines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бардымова Т.П., Колесникова Л.И., Петрова В.А. Перекисное окисление липидов и антиоксидантная система у больных сахарным диабетом 2-го типа // Бюллетень ВСНЦ СО РАМН. - 2005. - № 6. - С. 11-14.</mixed-citation><mixed-citation xml:lang="en">Бардымова Т.П., Колесникова Л.И., Петрова В.А. Перекисное окисление липидов и антиоксидантная система у больных сахарным диабетом 2-го типа // Бюллетень ВСНЦ СО РАМН. - 2005. - № 6. - С. 11-14.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Горюшкина О.А., Васильева Е.М. Антиоксидантная терапия в коррекции оксидативного стресса у больных ишемической болезнью сердца с сахарным диабетом 2-го типа // Вестник новых медицинских технологий. - 2013. - № 2. - С. 156-158</mixed-citation><mixed-citation xml:lang="en">Горюшкина О.А., Васильева Е.М. Антиоксидантная терапия в коррекции оксидативного стресса у больных ишемической болезнью сердца с сахарным диабетом 2-го типа // Вестник новых медицинских технологий. - 2013. - № 2. - С. 156-158</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Грачева С.А., Клефортова И.И., Шамхалова М.Ш. Распространённость сочетанного атеросклеротического поражения сосудов у больных сахарным диабетом // Сахарный диабет. - 2012. - № 1. - С. 49-55</mixed-citation><mixed-citation xml:lang="en">Грачева С.А., Клефортова И.И., Шамхалова М.Ш. Распространённость сочетанного атеросклеротического поражения сосудов у больных сахарным диабетом // Сахарный диабет. - 2012. - № 1. - С. 49-55</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития // Сахарный диабет. - 2015. - № 3. - С. 5-23.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития // Сахарный диабет. - 2015. - № 3. - С. 5-23.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Донцов А.В., Васильева Л.В. Инсулинорезистентность при метаболическом синдроме как показатель сердечно-сосудистого риска // Клиническая медицина. - 2016. - № 3. - С. 189-193.</mixed-citation><mixed-citation xml:lang="en">Донцов А.В., Васильева Л.В. Инсулинорезистентность при метаболическом синдроме как показатель сердечно-сосудистого риска // Клиническая медицина. - 2016. - № 3. - С. 189-193.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Доскина Е.В. Причины неудач в компенсации пациентов с сахарным диабетом 2-го типа. Роль постпрандиальной гликемии // Сахарный диабет. - 2010. - № 1. - С. 129-132.</mixed-citation><mixed-citation xml:lang="en">Доскина Е.В. Причины неудач в компенсации пациентов с сахарным диабетом 2-го типа. Роль постпрандиальной гликемии // Сахарный диабет. - 2010. - № 1. - С. 129-132.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Закирова Н.Э., Хафизов Н.Х., Карамова И.М., Закирова А.Н., Оганов Р.Г. Иммуновоспалительные реакции при ишемической болезни сердца // Рациональная фармакотерапия в кардиологии. - 2007. -№ 2. - С. 16-19.</mixed-citation><mixed-citation xml:lang="en">Закирова Н.Э., Хафизов Н.Х., Карамова И.М., Закирова А.Н., Оганов Р.Г. Иммуновоспалительные реакции при ишемической болезни сердца // Рациональная фармакотерапия в кардиологии. - 2007. -№ 2. - С. 16-19.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Литвинова Л.С., Кириенкова Е.В., Аксенова Н.Н., Газатова Н.Д., Затолокин П.А. Особенности клеточного иммунитета и цитокинового репертуара у пациентов с метаболическим синдромом // Бюллетень сибирской медицины. - 2012. - № 3. - С. 53-58.</mixed-citation><mixed-citation xml:lang="en">Литвинова Л.С., Кириенкова Е.В., Аксенова Н.Н., Газатова Н.Д., Затолокин П.А. Особенности клеточного иммунитета и цитокинового репертуара у пациентов с метаболическим синдромом // Бюллетень сибирской медицины. - 2012. - № 3. - С. 53-58.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Сахарный диабет 2-го типа: от теории к практике / Под ред. И.И. Дедова, М.В. Шестаковой. - М.: МИА, 2016. - 571 с.10. Шварц В. Воспаление жировой ткани. Часть 2. Патогенетическая роль при сахарном диабете 2-го типа // Проблемы эндокринологии. - 2009. - № 5. -С. 43-48.</mixed-citation><mixed-citation xml:lang="en">Сахарный диабет 2-го типа: от теории к практике / Под ред. И.И. Дедова, М.В. Шестаковой. - М.: МИА, 2016. - 571 с.10. Шварц В. Воспаление жировой ткани. Часть 2. Патогенетическая роль при сахарном диабете 2-го типа // Проблемы эндокринологии. - 2009. - № 5. -С. 43-48.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова М.В., Чазова И.Е., Шестакова Е.А. Российское многоцентровое скрининговое исследование по выявлению недиагностированного сахарного диабета 2-го типа у пациентов с сердечно-сосудистой патологией // Сахарный диабет. - 2016. - № 1. -С. 24-29.</mixed-citation><mixed-citation xml:lang="en">Шестакова М.В., Чазова И.Е., Шестакова Е.А. Российское многоцентровое скрининговое исследование по выявлению недиагностированного сахарного диабета 2-го типа у пациентов с сердечно-сосудистой патологией // Сахарный диабет. - 2016. - № 1. -С. 24-29.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Эссенциальная артериальная гипертензия и гены ренинангиотензиновой системы / Под ред. Л.И. Колесниковой. - Новосибирск: Наука, 2008. -108 с.</mixed-citation><mixed-citation xml:lang="en">Эссенциальная артериальная гипертензия и гены ренинангиотензиновой системы / Под ред. Л.И. Колесниковой. - Новосибирск: Наука, 2008. -108 с.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Abbatecola A.M., Paolisso G., Sinclair A.J. (2015). Treating diabetes mellitus in older and oldest old people. Curr. Pharm. Des., 21, 1665-1671.</mixed-citation><mixed-citation xml:lang="en">Abbatecola A.M., Paolisso G., Sinclair A.J. (2015). Treating diabetes mellitus in older and oldest old people. Curr. Pharm. Des., 21, 1665-1671.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Amar J., Fauvel J., Drouet L., Ruidavets J.B., Perret B., Chamontin B., Boccalon H., Ferrieres J. (2006). Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J. Hypertens., 6, 1083-1088.</mixed-citation><mixed-citation xml:lang="en">Amar J., Fauvel J., Drouet L., Ruidavets J.B., Perret B., Chamontin B., Boccalon H., Ferrieres J. (2006). Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J. Hypertens., 6, 1083-1088.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Antoniades C., Tousoulis D., Tountas C., Tentolouris C., Toutouza M., Vasiliadou C., Tsioufis C., Toutouzas P., Stefanadis C. (2004). Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet. Med., 6, 552-558.</mixed-citation><mixed-citation xml:lang="en">Antoniades C., Tousoulis D., Tountas C., Tentolouris C., Toutouza M., Vasiliadou C., Tsioufis C., Toutouzas P., Stefanadis C. (2004). Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet. Med., 6, 552-558.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Brand M.D., Affourtit C., Esteves T.C., Green K., Lambert A.J., Miwa S., Pakay J.L., Parker N. (2004). Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med., 37, 755-767.</mixed-citation><mixed-citation xml:lang="en">Brand M.D., Affourtit C., Esteves T.C., Green K., Lambert A.J., Miwa S., Pakay J.L., Parker N. (2004). Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med., 37, 755-767.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., Pignone M.P., Plutzky J., Porte D., Redberg R., Stitzel K.F., Stone N.J.; American Heart Association; American Diabetes Association. (2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115 (1), 114-126.</mixed-citation><mixed-citation xml:lang="en">Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., Pignone M.P., Plutzky J., Porte D., Redberg R., Stitzel K.F., Stone N.J.; American Heart Association; American Diabetes Association. (2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115 (1), 114-126.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chuengsamarn S., Rattanamongkolgul S., Sittithumcharee G., Jirawatnotai S. (2016). Association of serum high-sensitivity C-reactive protein with metabolic control and diabetic chronic vascular complications in patients with type 2 diabetes. Diabetes Metab. Syndr., 16, 30141-30142.</mixed-citation><mixed-citation xml:lang="en">Chuengsamarn S., Rattanamongkolgul S., Sittithumcharee G., Jirawatnotai S. (2016). Association of serum high-sensitivity C-reactive protein with metabolic control and diabetic chronic vascular complications in patients with type 2 diabetes. Diabetes Metab. Syndr., 16, 30141-30142.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cubbon R.M., Adams B., Rajwani A., Mercer B.N., Patel P.A., Cherardi G., Gale C.P., Batin P.D., Ajjan R., Kearney L., Wheatcroft S.B., Sapsford R.J., Witte K.K., Kearney M.T. (2013). Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemicaetiology. Diab. Vasc. Dis. Res., 10 (4), 330-336.</mixed-citation><mixed-citation xml:lang="en">Cubbon R.M., Adams B., Rajwani A., Mercer B.N., Patel P.A., Cherardi G., Gale C.P., Batin P.D., Ajjan R., Kearney L., Wheatcroft S.B., Sapsford R.J., Witte K.K., Kearney M.T. (2013). Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemicaetiology. Diab. Vasc. Dis. Res., 10 (4), 330-336.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Deedwania P.C. (2003). Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. Am. J. Cardiol., 91 (1), 68-71.</mixed-citation><mixed-citation xml:lang="en">Deedwania P.C. (2003). Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. Am. J. Cardiol., 91 (1), 68-71.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dinarello C.A. (2006). Interleukin 1 beta and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr., 83 (2), 447-455.</mixed-citation><mixed-citation xml:lang="en">Dinarello C.A. (2006). Interleukin 1 beta and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr., 83 (2), 447-455.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). (2001). JAMA, 285, 2486-2497.</mixed-citation><mixed-citation xml:lang="en">Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). (2001). JAMA, 285, 2486-2497.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Galis Z.S., Sukhova G.K., Lark M.W., Libby P. (1994). Increased expression of matrix matalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerosis plaques. J. Clin. Invest., 94 (6), 2493-2503.</mixed-citation><mixed-citation xml:lang="en">Galis Z.S., Sukhova G.K., Lark M.W., Libby P. (1994). Increased expression of matrix matalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerosis plaques. J. Clin. Invest., 94 (6), 2493-2503.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia C., Feve B., Ferré P., Halimi S., Baizri H., Bordier L., Guiu G., Dupuy O., Bauduceau B., Mayaudon H. (2010). Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab., 36 (5), 327-338.</mixed-citation><mixed-citation xml:lang="en">Garcia C., Feve B., Ferré P., Halimi S., Baizri H., Bordier L., Guiu G., Dupuy O., Bauduceau B., Mayaudon H. (2010). Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab., 36 (5), 327-338.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Greenland P., Abrams J., Aurigemma G.P., Bond M.G., Clark L.T., Criqui M.H., Crouse J.R. 3rd, Friedman L., Fuster V., Herrington D.M., Kuller L.H., Ridker P.M., Roberts W.C., Stanford W., Stone N., Swan H.J., Taubert K.A., Wexler L. (2000). Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation, 101, 16-22.</mixed-citation><mixed-citation xml:lang="en">Greenland P., Abrams J., Aurigemma G.P., Bond M.G., Clark L.T., Criqui M.H., Crouse J.R. 3rd, Friedman L., Fuster V., Herrington D.M., Kuller L.H., Ridker P.M., Roberts W.C., Stanford W., Stone N., Swan H.J., Taubert K.A., Wexler L. (2000). Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation, 101, 16-22.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Gulli G., Ferrannini E., Stern M., Haffner S., DeFronzo R.A. (1992) The metabolic profile of NIDDM is fully established in glucose tolerant offspring of two Mexican-American NIDDM parents. Diabetes, 41, 1575-1586.</mixed-citation><mixed-citation xml:lang="en">Gulli G., Ferrannini E., Stern M., Haffner S., DeFronzo R.A. (1992) The metabolic profile of NIDDM is fully established in glucose tolerant offspring of two Mexican-American NIDDM parents. Diabetes, 41, 1575-1586.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Haffner S.M., Mykkänen L., Valdez R.A., Stern M.P., Holloway D.L., Monterrosa A., Bowsher R.R. (1994). Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J. Clin. Endocrinol. Metab., 79, 1806-1810.</mixed-citation><mixed-citation xml:lang="en">Haffner S.M., Mykkänen L., Valdez R.A., Stern M.P., Holloway D.L., Monterrosa A., Bowsher R.R. (1994). Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J. Clin. Endocrinol. Metab., 79, 1806-1810.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hotamisligil G.S. (2006). Inflammation and metabolic disorders. Nature, 444 (7121), 860-867.</mixed-citation><mixed-citation xml:lang="en">Hotamisligil G.S. (2006). Inflammation and metabolic disorders. Nature, 444 (7121), 860-867.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">IDF Diabetes Atlas, 7th ed. (2015). Available at: http://www.diabetesatlas.org/resources/2015-atlas.html.</mixed-citation><mixed-citation xml:lang="en">IDF Diabetes Atlas, 7th ed. (2015). Available at: http://www.diabetesatlas.org/resources/2015-atlas.html.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Iozzo P., Chareonthaitawee P., Dutka D., Betteridge D.J., Ferrannini E., Camici P.G. (2002). Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes, 51, 3020-3024.</mixed-citation><mixed-citation xml:lang="en">Iozzo P., Chareonthaitawee P., Dutka D., Betteridge D.J., Ferrannini E., Camici P.G. (2002). Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes, 51, 3020-3024.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Jialal I., Devaraj S., Venugopal S.K. (2004). C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 44, 6-11.</mixed-citation><mixed-citation xml:lang="en">Jialal I., Devaraj S., Venugopal S.K. (2004). C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 44, 6-11.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kendall M., Sobel B.E., Coulston A.M. (2003). The insulin resistance syndrome and coronary artery disease. Coron. Artery. Dis., 14 (4), 335-348.</mixed-citation><mixed-citation xml:lang="en">Kendall M., Sobel B.E., Coulston A.M. (2003). The insulin resistance syndrome and coronary artery disease. Coron. Artery. Dis., 14 (4), 335-348.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lautamäki R., Airaksinen K.E., Seppänen M., Toikka J., Luotolahti M., Ball E., Borra R., Härkönen R., Iozzo P., Stewart M., Knuuti J., Nuutila P. (2005). Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. Diabetes, 54, 2787-2794.</mixed-citation><mixed-citation xml:lang="en">Lautamäki R., Airaksinen K.E., Seppänen M., Toikka J., Luotolahti M., Ball E., Borra R., Härkönen R., Iozzo P., Stewart M., Knuuti J., Nuutila P. (2005). Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. Diabetes, 54, 2787-2794.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lee A.Y., Chung S.S. (1999). Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J., 13, 23-30.</mixed-citation><mixed-citation xml:lang="en">Lee A.Y., Chung S.S. (1999). Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J., 13, 23-30.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Maggioni A.P., Anand I., Gottlieb S.O. (2002). Effects of valsari'an on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J. Am. Coll. Cardiol., 40, 1414-1421.</mixed-citation><mixed-citation xml:lang="en">Maggioni A.P., Anand I., Gottlieb S.O. (2002). Effects of valsari'an on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J. Am. Coll. Cardiol., 40, 1414-1421.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Miyamoto S., Rubio M., Sussman M.A. (2009). Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc. Res., 1, 272-285.</mixed-citation><mixed-citation xml:lang="en">Miyamoto S., Rubio M., Sussman M.A. (2009). Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc. Res., 1, 272-285.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Muris D.M., Houben A.J., Kroon A.A., Henry R.M., van der Kallen C.J., Sep S.J., Koster A., Dagnelie P.C., Schram M.T., Stehouwer C.D. (2014). Age, waist circumference and blood pressure are associated with skin microvascular flow motion: the Maastricht Study. J. Hypertens., 32 (12), 2439-2449.</mixed-citation><mixed-citation xml:lang="en">Muris D.M., Houben A.J., Kroon A.A., Henry R.M., van der Kallen C.J., Sep S.J., Koster A., Dagnelie P.C., Schram M.T., Stehouwer C.D. (2014). Age, waist circumference and blood pressure are associated with skin microvascular flow motion: the Maastricht Study. J. Hypertens., 32 (12), 2439-2449.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Orchard T.J., Costacou T., Kretowski A., Nesto R.W. (2006). Type 1 diabetes and coronary artery disease. Diabetes Care, 11, 2528-2538.</mixed-citation><mixed-citation xml:lang="en">Orchard T.J., Costacou T., Kretowski A., Nesto R.W. (2006). Type 1 diabetes and coronary artery disease. Diabetes Care, 11, 2528-2538.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Prentki M., Nolan C.J. (2006). Islet ß cell failure in type 2 diabetes. J. Clin. Invest., 116 (7), 1802-1812.</mixed-citation><mixed-citation xml:lang="en">Prentki M., Nolan C.J. (2006). Islet ß cell failure in type 2 diabetes. J. Clin. Invest., 116 (7), 1802-1812.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ramana K.V., Friedrich B., Tammali R., West M.B., Bhatnagar., Srivastava S.K. (2005). Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 54, 818-829.</mixed-citation><mixed-citation xml:lang="en">Ramana K.V., Friedrich B., Tammali R., West M.B., Bhatnagar., Srivastava S.K. (2005). Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 54, 818-829.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Reaven G.M. (1998). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.</mixed-citation><mixed-citation xml:lang="en">Reaven G.M. (1998). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. (2000). Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 101, 1767-1772.</mixed-citation><mixed-citation xml:lang="en">Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. (2000). Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 101, 1767-1772.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Schauer I.E., Shell-Bergeon J.K., Bergman B.C., Maahs D.M., Kretowski A., Eckel R.H., Revers M. (2011). Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes, 1, 306-314.</mixed-citation><mixed-citation xml:lang="en">Schauer I.E., Shell-Bergeon J.K., Bergman B.C., Maahs D.M., Kretowski A., Eckel R.H., Revers M. (2011). Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes, 1, 306-314.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Splansky G.L., Corey D., Yang Q., Atwood L.D., Cupples L.A., Benjamin E.J., D'Agostino R.B. Sr, Fox C.S., Larson M.G., Murabito J.M., O’Donnell C.J., Vasan R.S., Wolf P.A., Levy D. (2007). The third generation cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am. J. Epidemiol., 165, 1328-1335.</mixed-citation><mixed-citation xml:lang="en">Splansky G.L., Corey D., Yang Q., Atwood L.D., Cupples L.A., Benjamin E.J., D'Agostino R.B. Sr, Fox C.S., Larson M.G., Murabito J.M., O’Donnell C.J., Vasan R.S., Wolf P.A., Levy D. (2007). The third generation cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am. J. Epidemiol., 165, 1328-1335.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. BMJ, 321, 405-412.</mixed-citation><mixed-citation xml:lang="en">Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. BMJ, 321, 405-412.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Tappia P.S., Dent M.R., Dhalla N.S. (2006). Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic. Biol. Med., 41, 349-361.</mixed-citation><mixed-citation xml:lang="en">Tappia P.S., Dent M.R., Dhalla N.S. (2006). Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic. Biol. Med., 41, 349-361.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Taubert D., Rosenkranz A., Berkels R., Roesen R., Schmig E. (2004). Acute effects of glucose and insulin on vascular endothelium. Diabetologia, 47, 2059-2071.</mixed-citation><mixed-citation xml:lang="en">Taubert D., Rosenkranz A., Berkels R., Roesen R., Schmig E. (2004). Acute effects of glucose and insulin on vascular endothelium. Diabetologia, 47, 2059-2071.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Uptitchard J.E., Sutherland W.H., Mann J.I. (2000). Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Сare, 23, 733-738.</mixed-citation><mixed-citation xml:lang="en">Uptitchard J.E., Sutherland W.H., Mann J.I. (2000). Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Сare, 23, 733-738.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz M.B., Guray U., Guray Y., Altay H., Demirkan B., Caldir V., Cay S., Refiker M.E., Sasmaz H., Korkmaz S. (2005). Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coron. Artery Dis., 100, 561-562.</mixed-citation><mixed-citation xml:lang="en">Yilmaz M.B., Guray U., Guray Y., Altay H., Demirkan B., Caldir V., Cay S., Refiker M.E., Sasmaz H., Korkmaz S. (2005). Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coron. Artery Dis., 100, 561-562.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Young J., Libby P., Schonbeck U. (2002). Cytokines in the pathogenesis of atherosclerosis. Thrombos. Haemostas., 88, 554-567</mixed-citation><mixed-citation xml:lang="en">Young J., Libby P., Schonbeck U. (2002). Cytokines in the pathogenesis of atherosclerosis. Thrombos. Haemostas., 88, 554-567</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
